Taienkang announced that recently, its wholly-owned subsidiary Huabo Kaisheng participated in the 12th batch of centralized national drug procurement, and baritinib tablets were selected. During the procurement cycle, medical institutions prioritize the use of selected products. After Huabo Kaisheng subsequently signed a contract and implemented it, it is conducive to product release and market development, enhances brand influence, and has a positive impact on future performance, but there is uncertainty about follow-up matters such as the signing of procurement agreements and the impact on performance.

Taienkang announced that recently, its wholly-owned subsidiary Huabo Kaisheng participated in the 12th batch of centralized national drug procurement, and baritinib tablets were selected. During the procurement cycle, medical institutions prioritize the use of selected products. After Huabo Kaisheng subsequently signed a contract and implemented it, it is conducive to product release and market development, enhances brand influence, and has a positive impact on future performance, but there is uncertainty about follow-up matters such as the signing of procurement agreements and the impact on performance.